The cell cycle is governed by cyclin dependent kinases (cdks), which are activated by binding of cyclins, inhibited by cdk inhibitors and regulated by phosphorylation and dephosphorylation. Exposure to high dose dihydrotestosterone (DHT) inhibits population growth of the human prostate carcinoma cell line, LNCaP. To determine the mechanism of growth arrest by high dose DHT, we assayed the changes in cell cycle pro®le and the cell cycle regulators that mediate these eects. Treatment of asynchronously growing LNCaP cells with 100 nM DHT caused a G1 arrest. The proportion of cells in S phase fell from 22 to 2%, while the G1 fraction rose from 74 to 92% by 24 h. Loss of phosphorylation of the retinoblastoma protein was noted and cdk4 and cyclin E/ cdk2 activities fell. Inhibition of these G1 cyclin dependent kinases was not due to loss of either cyclin or cdk proteins nor to increases in the cdk inhibitors p16
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Introduction
Androgen interaction with the androgen receptor (AR) is important for growth and development of both the normal prostate and of prostate cancer (Hakimi et al., 1996) . At present, the most eective therapy for prostate cancer is reduction of testosterone or of its most active metabolite, 5a-dihydrotestosterone (DHT) by dierent treatments collectively referred to as androgen ablation (Catalona, 1994) . However, tumor progression to an androgen insensitive state severely limits the ecacy of these treatments. We have investigated how this steroid pathway in¯uences key cell cycle regulators in the androgen sensitive, human prostate cancer cell line, LNCaP. An understanding of how cell cycle progression is in¯uenced by androgen pathways, and how these mechanisms are disrupted in prostate cancer progression, may lead ultimately to new methods of achieving cytostasis in hormone resistant prostate cancers.
Progression through the cell cycle is governed by a family of cyclin dependent kinases (cdks), whose activity is regulated by phosphorylation (Solomon, 1993) , activated by binding of cyclins (Morgan, 1995; Sherr, 1994) and inhibited by the cdk inhibitors Sherr and Roberts, 1995) . The cdks regulate biochemical pathways, or checkpoints, which integrate mitogenic and growth inhibitory signals, monitor chromosome integrity, and coordinate cell cycle transitions (Hartwell, 1992; Murray, 1992) . Passage through G1 into S phase is regulated by the activities of cyclin D-, cyclin E-, and cyclin Aassociated kinases. Cyclin B-dependent kinases regulate the G2/M transition.
Two families of cdk inhibitors mediate cell cycle arrest following growth inhibitory stimuli (Sherr and Roberts, 1995, 1999 Kip2 , bind and inhibit target cyclin/cdk complexes. The cdk inhibitor, p27, acts during G0 and the early G1 phase of the cell cycle to inhibit G1 cyclin/cdk complexes (Polyak et al., 1994a,b; Toyoshima and Hunter, 1994; Slingerland et al., 1994; Hengst et al., 1994) . In many cell types, p27 is essential for quiescence. Antisense p27 inhibits exit from the cell cycle following serum withdrawal (Coats et al., 1996; Rivard et al., 1996) and antisense p27 stimulates estradiol depleted quiescent MCF-7 breast cancer cells to re-enter cell cycle (Cariou, Donovan and Slingerland, in preparation) . p27 levels are regulated by posttranscriptional mechanisms including both translation and proteolysis (Hengst and Reed, 1996; Pagano et al., 1995; Millard et al., 1997) . In human cell lines, phosphorylation of p27 is maximal in G1, just prior to the drop in p27 protein that occurs at S phase (Pagano et al., 1996) . Phosphorylation of p27 triggers its proteolytic degradation (Vlach et al., 1997; Shea et al., 1997; Montagnoli et al., 1999; Tsvetkov et al., 1999) , as is the case for the yeast cdk inhibitor Sic1 (Schneider et al., 1996; Tyers, 1996) . p27 increases during dierentiation in many cell types, including dierentiation induced by vitamin D3 (Hengst and Reed, 1996; Wang et al., 1996) and by androgen in the prostatic epithelium (Chen et al., 1996) . p27 knockout cells manifest altered dierentiation programs (Casaccia-Bonne®l et al., 1997) . Indeed, p27 knockout mice develop multiple organ hyperplasia (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) , including prostatic hyperplasia (CordonCardo et al., 1998) , underlining the importance of p27 as an inhibitor of prostate cell proliferation.
Increasing evidence suggests that the cyclins, cdks and cdk inhibitors are either themselves targets for genetic change in cancer or are disrupted secondarily by other oncogenic events (Hunter and Pines, 1994) . Since they oppose mitogenic stimuli, the cdk inhibitors are good candidates as tumor suppressors. Although genetic changes in the p16 gene support a tumor suppressor (TS) role for this inhibitor in cancers , mutations in p27 have been identi®ed only rarely (Kawamata et al., 1995; Pietenpol et al., 1995; PonceCastaneda et al., 1995) . A reduction in p27 protein could contribute to resistance to growth inhibitory factors, deregulation of cell proliferation, and oncogenic change. Although normal human epithelia of the breast, prostate, lung, and colon express high levels of p27 protein, this protein is frequently reduced in primary carcinomas at these sites (reviewed in Cariou et al., 1998) . The reduction of p27 protein is of prognostic importance in these cancers and correlates with an aggressive tumor phenotype in vivo (Catzavelos et al., 1997; Loda et al., 1997; Porter et al., 1997; Tan et al., 1997; Mori et al., 1997; Esposito et al., 1997; Tsihlias et al., 1998) . Enhanced proteolytic degradation may underlie the loss of p27 in tumor cells (Catzavelos et al., 1997; Loda et al., 1997; Esposito et al., 1997) . Thus, changes in the post-translational mechanisms which target p27 for degradation, may be germane to oncogenesis and/or tumor progression.
In a study of p27 immunostaining in primary prostate cancer, we found that loss of p27 protein was an independent prognostic factor, predicting reduced time to recurrence following radical prostatectomy (P=0.047, risk ratio 2.08) (Tsihlias et al., 1998) . In a small subset of patients, androgen ablation therapy prior to tumor removal appeared to increase p27 protein, raising the possibility that androgens may modulate p27 degradation pathways in vivo. In the present study, the eect of high dose androgen on cell cycle progression was investigated in a model of human prostate cancer, the LNCaP cell line.
LNCaP is an androgen-sensitive human prostate cancer cell line derived from a metastasis to a supraclavicular lymph node (Horoszewicz et al., 1983) . The line has an aneuploid human male karyotype, and is tumorigenic when implanted into nude mice. The potent androgen, 5a-dihydrotestosterone (DHT), modulates LNCaP proliferation in a well-characterized fashion. DHT stimulates proliferation at concentrations between 0.1 and 1.0 nM DHT and proliferation is inhibited at DHT concentrations below 0.1 nM or above 10 nM DHT. Androgens have also been shown to mediate biphasic growth response in the prostate in vivo. Low dose androgen administered to castrate rats will reverse prostate atrophy and induce proliferation in the prostate gland. Higher doses of androgen cause growth arrest by inducing dierentiation of prostate epithelial cells (Chen et al., 1996) . Because our study of primary tumors suggested that p27 regulation may be importantly altered in human prostate cancers, we wished to explore further how androgen may modulate the cell cycle and p27 function in the prostate cancer line, LNCaP.
Results

nM dihydrotestosterone causes G1 arrest of LNCaP
Treatment of asynchronously growing LNCaP cells with 100 nM DHT for 24 h induced a G1 arrest. The proportion of cells in G1 went from 70%, in the asynchronously growing untreated cells, to 92% at maximal arrest by 48 h. Cells in S phase fell from 22% of the untreated population to 2% within 24 h ( Figure  1) . A sub-G1 population was not observed. No signi®cant growth arrest was observed when cells were cultured in media supplemented with 1 and 10 nM DHT (data not shown).
The cell cycle arrest persisted for up to 96 h in media supplemented with DHT. This DHT-mediated cell cycle arrest was not accompanied by cytotoxicity, based on morphological appearance and the use of Trypan blue exclusion staining. The proportion of cells that failed to exclude Trypan blue was similar in treated and untreated cells. Treatment of LNCaP cells with 50 nM DHT also caused a G1 arrest within 48 h. To determine whether high dose DHT was inducing a form of irreversible dierentiation, cells were cultured for 48 h in 50 and 100 nM DHT and then transferred to media without additional DHT for a further 24 h. Upon removal of supplemental DHT from the culture media, cells underwent a prompt release from G1 arrest, showing an asynchronous cell cycle pro®le within 24 h (S phase fraction 20%) ( Table 1) .
To determine whether the eects of 100 nM DHT on prostate cancer cell proliferation could occur in the absence of the AR and AR signaling, two steroidindependent prostate cancer lines, PC-3 (Kaighn et al., 1979) and DU145 (Stone et al., 1978) were treated with 100 nM DHT. Neither the PC-3 nor the DU145 prostate cancer cell lines express detectable AR (Kaighn et al., 1979; Stone et al., 1978) . The addition of 100 nM DHT to the culture medium had no eect on either PC-3 or DU145 cell proliferation (data not shown). Treatment of LNCaP cells with 100 nM DHT for 48 h led to an increased secretion of prostate speci®c antigen as determined by Hybritech assay on culture media. PSA concentration (ng/ml) in conditioned media from cells with/without 100 nM DHT was 383.5/167.5 and 443.1/340.3 on two separate occasions. Although the results were not normalized for cell number, cells were initially plated equally. After 48 h, the number of cells on DHT treated plates would be less than that on untreated plates. Thus, relative cellular production of secreted PSA was increased by exposure to 100 nM DHT. A Western blot did not demonstrate any dierence in cellular PSA levels as cells underwent arrest (data not shown).
DHT mediated G1 arrest is accompanied by accumulation of nuclear p27 protein
Immunohistochemistry performed on asynchronous populations of LNCaP cells demonstrated a heterogeneous nuclear immunoreactivity for p27. Cells arrested in G1 after treatment with 100 nM DHT for 48 h demonstrated uniformly strong nuclear staining for p27 protein (Figure 2 ). Controls reacted with secondary antibody alone did not show any signi®cant nuclear staining. Pre-adsorption of the primary antibody with blocking peptide abolished the nuclear staining (data not shown).
Western analysis at intervals after treatment with 100 nM DHT showed loss of phosphorylation of the retinoblastoma protein (pRb) within 16 h, with predominantly hypophosphorylated pRb detected at 48 h. There was no appreciable change in the protein levels of cdk2, cdk4, and cdk6, cyclins D1 and E, or the cdk inhibitors p16
INK4A and p21
Cip1
. Levels of cyclins A and B1 fell signi®cantly. This is consistent with the DHTmediated inhibition of entrance into S and G2/M phases, where peak expression of these latter two proteins is known to occur. An increase in p27 protein levels was appreciable within 4 h after addition of DHT, with peak levels fourfold above baseline detected by 48 h, as determined by densitometry ( Figure 3 ).
The increase in p27 saturates and inhibits cyclin E/cdk2 in DHT-arrested LNCaP
Inhibition of cyclin E/cdk2 activity was notable within 12 h after the addition of 100 nM DHT to the asynchronously growing cells, with minimal activity detected at 24 h ( Figure 4b ). To further investigate the mechanism of inhibition of cyclin E/cdk2, these complexes were examined by immunoprecipitation of cyclin E followed by Western blotting to detect associated proteins. No dissociation of cyclin E/cdk2 complexes was observed, however, the amount of CAKactivated threonine 160 phosphorylated cdk2 bound to cyclin E decreased. Phosphorylation by cdk activating kinase (CAK) shifts cdk2 to its faster mobility form on SDS ± PAGE (Gu et al., 1992) . The amount of cyclin Eassociated p21 fell, suggesting that p21 is not relevant to this form of cyclin E/cdk2 inhibition. The amount of cyclin E-associated p27 increased 3 ± 4-fold, by densitometry, as the cells entered G1 arrest (Figure 4a ). In other cellular contexts, such an increase in p27 has been shown to saturate cellular cyclin E/cdk2 (Reynisdottir et al., 1995) .
To determine whether this increase in p27 was sucient to saturate target cyclin E/cdk2 and induce cell cycle arrest, p27 was immunodepleted by three serial immunoprecipitations from both asynchronously growing cell lysates and from DHT-arrested cell lysates. Cyclin E immune complexes were examined before and after p27-immunodepletion. p27 immunodepletion caused a signi®cant reduction of cyclin E protein from asynchronously growing cell lysates (Figure 4c ). This re¯ects the substantial proportion of G1 phase cells in an asynchronous population of LNCaP. In spite of a signi®cant reduction in the level of cyclin E, the remaining cyclin E immune complexes showed almost the same kinase activity after p27 immunodepletion as before (Figure 4c, left panel) . This is consistent with most p27-bound cyclin E complexes having minimal kinase activity. There was virtually no detectable cyclin E remaining after p27 immunodepletion of DHT-arrested cell lysates. Thus, the increase in p27 by DHT treatment was sucient to saturate and inhibit the cellular cyclin E/cdk2 complexes. Antisense p27 failed to prevent the increased binding of p27 to cyclin E after high dose DHT Antisense p27 oligonucleotides (ASp27) were transfected into asynchronously growing LNCaP cells. Six hours post transfection, 100 nM DHT was added to control (lipid alone), mismatch oligonucleotide (MSp27) and ASp27 transfected cells. In both oligonucleotide-transfected and non-transfected controls, 100 nM DHT induced G1 arrest. MSp27 and control cells showed the same increase in p27 by DHT as did LNCaP treated with 100 nM DHT alone. ASp27 prevented the fourfold rise in p27 protein following DHT treatment. p27 levels in the cells treated with ASp27 and DHT together were similar to untreated asynchronously growing LNCaP. However, when cyclin E immune complexes were analysed, ASp27 treated cells still showed an increase in the binding of p27 to cyclin E complexes following 100 nM DHT, in spite of the modest reduction in total p27 levels. ASp27 treatment did not reduce total p27 protein levels to a sucient degree in LNCaP to prevent the DHTmediated increased association of p27 with its target kinase cyclin E/cdk2 (data not shown).
Inhibition of cyclin D-bound cdk4 by high dose DHT
The cyclin D-associated kinases also function in G1 to regulate the transition into S phase. To assay the eects of 100 nM DHT on these complexes, cdk4 was immunoprecipitated and kinase activity assayed at various intervals during the arrest of the LNCaP cells. Cdk4 activity was strongly inhibited by treatment with 100 nM DHT (Figure 5b ). Immunoprecipitation of cdk4 and its associated complexes did not demonstrate any dissociation of cyclin D1 from cdk4. The level of cdk4-bound p16 remained unchanged. There was a rise in p15 association with cdk4 between 0 ± 12 h after addition of DHT, which persisted to 24 h. Between 24 ± 48 h, there was no further reduction in the per cent S phase cells, and cdk4-bound p15 actually decreased slightly by 48 h, possibly re¯ecting progression into a quiescent state. The levels of p21 and p27 bound to cdk4 decreased as cells underwent arrest.
Discussion
The LNCaP cell line is the most commonly studied model of androgen-sensitive prostate cancer. This cell line shows a characteristic bell shaped growth curve in response to increasing concentrations of androgen in the growth media (Horoszewicz et al., 1983; Lee et al., 1995; Kim et al., 1996) . Although the dose-dependent dierences in the eects androgen on cell numbers have been known for nearly two decades, the mechanism of the growth inhibition by high dose androgen was poorly understood. Androgens are required for normal growth and dierentiation in prostate epithelial cells. Chen et al. (1996) studied the eects of androgen on the cell cycle of normal prostate in vivo in rats. Castration resulted in atrophy of the gland due to Figure 3 Cell cycle regulators during G1 arrest by DHT. Cells were harvested at indicated time intervals after addition of 100 nM DHT to culture media. Lysates were prepared and resolved using 17.5% SDS ± PAGE. Proteins were detected by immunoblotting with the indicated antibodies p27 in G1 arrest of prostate cancer cells J Tsihlias et al apoptosis and arrest of surviving cells. Re-administration of testosterone induced transient epithelial cell proliferation followed by decreased cellular proliferation and an increase in p27. It was postulated that the increased p27 was playing a role to inhibit proliferation as regenerating prostatic tissue underwent steroidmediated dierentiation. The paradoxical eects of androgen stimulation in LNCaP (growth stimulation at low concentrations of androgen, growth inhibition with increased PSA secretion at high concentrations) may represent a normal physiological mechanism that has been retained by this tumor cell line. Several lines of evidence suggest that the G1 arrest by high dose DHT is an AR mediated eect. In our study, as in others , high dose DHT induced an increase in PSA secretion by the LNCaP cells. PSA is a serine protease that is normally secreted by the prostatic epithelium. We demonstrated higher PSA production in conditioned media from cells arrested after 48 h in 100 nM DHT than in cells without added androgen. This result and our observation that cellular PSA levels were not increased by Western analysis are consistent with a DHT-induced increase in secretion of PSA. Treatment of ARnegative PC-3 cells and DU145 cells with 100 nM DHT aected neither cellular proliferation nor PSA secretion (not shown). Furthermore, PC-3 cells that have been genetically engineered to express the AR show growth arrest in response to androgen treatment (E Brown, personal communication).
The present study demonstrates that the decreased rate of growth for LNCaP at high doses of DHT is due to G1 arrest and not to cell death. Growth inhibition with G1 arrest was demonstrated at doses of 50 and 100 nM DHT, whereas, no signi®cant growth arrest was observed with doses between 1 ± 10 nM DHT. We saw no morphological evidence of cell toxicity and Trypan blue exclusion did not dier between treated and untreated cells. Furthermore, the G1 arrest appeared fully reversible on removal of the high dose DHT at 48 h. The longest treatment interval was 96 h, with maximal arrest noted at 24 h. Whether exposure to 100 nM DHT longer than 96 h might induce an irreversible G1 arrest is not known. Figure 4 p27 saturates cyclin E/cdk2 complexes and inhibits this kinase following treatment of asynchronously growing LNCaP with 100 nM DHT. (a) Cyclin E immune complexes. Cells were recovered at intervals after addition of DHT to culture media. DNA pro®les were determined by FACS analysis, and the percentage of cells in G1, S, and G2/M is indicated for each time point. Cyclin E was immunoprecipitated, complexes resolved by SDS ± PAGE and immunoblots were reacted with antibodies to detect associated proteins. (b) Cyclin E/cdk2 Kinase Activity. Cyclin E was immunoprecipitated from lysates collected in (a) above and associated kinase activities were assayed. Reaction products were resolved by SDS ± PAGE, and gels were dried and exposed to ®lm. Radioactivity in the Histone H1 substrate was quantitated by PhosphorImager and expressed as a percentage of maximum activity after subtraction of background from control immunoprecipitates. (c) p27 immunodepletion experiments. p27 was serially immunodepleted from lysates collected at either 0 or 48 h after addition of 100 nM DHT to media. Cyclin E-associated proteins and cyclin E-associated kinase activities were assayed before and after p27 immunodepletion from the T=0 and T=48 h samples p27 in G1 arrest of prostate cancer cells
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High dose DHT caused a loss of pRB phosphorylation as has been observed in other forms of G1 arrest (Laiho et al., 1990; Sandhu et al., 1997) . Hypophosphorylated pRB binds and inactivates E2F, thereby inhibiting the function of that transcription factor, and precluding transcription of genes required for S phase entry (DeGregori et al., 1995) . Phosphorylation of pRB leads to its dissociation from E2F, and to E2F activation (Chellappan et al., 1991) . The pRB gene is wild type in LNCaP (Peehl, 1994) . Since both cyclin Dassociated kinases and cyclin E/cdk2 activities contribute to pRB phosphorylation (Sherr and Roberts, 1995) , the eects of DHT on these cyclin/cdks were assayed.
Cyclin E-dependent kinase activity fell as cells underwent arrest. This was accompanied by a fourfold overall increase in p27 protein. More importantly, the increase in p27 protein was sucient to fully saturate cyclin E/cdk2 complexes. p27-immunodepletion demonstrated that essentially all of the cellular cyclin E was bound to p27 in these DHT-arrested cells. This supports the conclusion that the increase in p27 contributes causally to cyclin E/cdk2 inhibition and to the G1 arrest observed. In other systems, a similar increase in p27 levels has been shown to be sucient to saturate and inactivate cyclin E/cdk2 (Reynisdottir et al., 1995) . The fact that cyclin E-associated p21 fell as cells arrested, suggests that p21 is not likely to be involved in inhibition of this kinase.
ASp27 treatment prevented the fourfold increase in p27 levels following exposure to 100 nM DHT. However, ASp27 failed to prevent DHT-mediated G1 arrest. In spite of the modest reduction in p27 protein levels, the increased association of p27 with cyclin E/ cdk2 complexes was intact in ASp27 treated cells arrested by 100 nM DHT. This suggests that factors that lead to an increased anity of binding of p27 to cyclin E/cdk2 following DHT treatment may be more important to the inhibition of this kinase than the increase in p27 protein levels alone.
Cdk activating kinase (CAK) mediated phosphorylation of cdk2 on threonine 160 is required for catalytic activity (Gu et al., 1992) . In this study, cyclin E-bound cdk2 showed a progressive loss of CAK activation, with accumulation of the slower mobility form of cyclin E-bound cdk2. Kato et al. (1994) have demonstrated that p27 can inhibit CAK activation of cyclin D-associated cdk4 during cyclic AMP mediated G1 arrest in macrophages. Increased binding of p27 to cyclin E/cdk2 may modulate the conformation of these complexes and block the access of CAK to its catalytic sites on cdk2, thereby preventing the activating phosphorylation of cdk2. A similar loss of CAK activation of cyclin E-bound cdk2 has been demonstrated in TGF-b arrested cells (Ko et al., 1993; Slingerland et al., 1994) .
Cdk4 kinase activity was also inhibited by 100 nM DHT. p16, p21, and p27 are not likely involved in the inhibition of this kinase, since p16 association with cdk4 remained constant and dissociation of p21 and p27 from cdk4 was observed. p15 binding to cdk4 was increased at 12 h and remained elevated until 24 h. The accumulation of p15 may facilitate dissociation of p21 and p27 from cdk4 complexes. Versions of this model of action for p15 have been suggested previously in G1 arrest due to TGF-b (Reynisdottir et al., 1995; Sandhu et al., 1997) . It is also possible that the anity of p27 for cyclin E/cdk2 is actively regulated as suggested by Shea et al. (1997) , and this may be independent of the eects of p15 on cyclin D/cdk4 complexes .
The INK4 family of cdk inhibitors have been shown to inactivate their target kinases by binding to them and displacing the associated cyclin (Parry et al., 1995; Sandhu et al., 1997) . Although we did not see cyclin D1 dissociation from cdk4 as kinase activity diminished, it is possible that p15 may have displaced cyclin D2 or D3. However, we were unable to detect cyclins D2 or D3 in cdk4 complexes using commercially available antibodies. Clearly, there may be more than one mechanism contributing to DHT-mediated G1 arrest. Although p27 appears to be important in the inhibition of cyclin E/cdk2, other mechanisms, including p15, may act to inhibit the D-type cyclin/cdks.
Since 1941, when Huggins and Hodges discovered that prostate cancer undergoes regression in response to castration, there have been few major advances in the management of metastatic prostate cancer (Huggins et al., 1941) . Leutinizing hormone releasing hormone (LHRH) analogs that induce castrate levels of testosterone have obviated the need for castration (Peeling, 1989) . In spite of advances in the hormonal therapy of prostate cancers, progression to a hormone independent state invariably occurs. Thus, there is clearly a need for development of novel treatment approaches for advanced prostate cancer. A greater understanding of how cell cycle regulators respond to androgenic stimuli in normal and malignant prostatic epithelial cells could lead to the identi®cation of new targets for therapy. The present study suggests that the increased levels of p27, and its binding and inhibition of cyclin E/cdk2 contribute to G1 arrest of LNCaP human prostate cancer cells in response to high doses of DHT.
Several other reports suggest a role for p27 as a mediator of G1 arrest in prostate cancer tissue culture models. G1 arrest of prostate cancer line DU145 induced by EGF receptor blockade involves upregulation of p27 protein and corresponding inhibition of cyclin E/cdk2 activity (Peng et al., 1996; Zi et al., 1998) . A subline of LNCaP developed by continuous culture in the absence of androgen is growth inhibited by low doses of androgen. In this LNCaP subline, loss of cdk2 activity was also correlated with accumulation of p27 (Kokontis et al., 1998) . In an androgen dependent mouse mammary carcinoma cell line, SC-3, G1 arrest upon androgen withdrawal is associated with a similar upregulation of p27 and the binding and inhibition of cdk2 by p27 (Menjo et al., 1998) . In these dierent tissue culture models, androgen mediates dierent eects on proliferation: in the one case, androgen induces growth arrest, whereas in the other, androgen withdrawal has this same eect. Interestingly, in each case, a similar mechanism of G1 arrest appears to be invoked, with upregulation of p27 leading to inhibition of cyclin E/cdk2 activity. Since the growth of prostate cancers in vivo can initially be restricted by anti-androgens, it would be of interest to determine whether p27 is up-regulated following androgen depletion of steroid-dependent prostate cancer.
Increasing data from studies of p27 in vivo, in human prostate cancers, suggest a role for this KIP in prostate epithelial cell growth. Several recent reports indicate a prognostic role for p27 in prostate cancer. Low or undetectable levels of p27 protein in primary prostate carcinoma have been shown to correlate with increased proliferative index (Guo et al., 1997) , increasing tumor grade (Tsihlias et al., 1998; Yang et al., 1998; Guo et al., 1997; Cote et al., 1998) shorter disease-free survival (Tsihlias et al., 1998; Yang et al., 1998; Cote et al., 1998; , and decreased overall survival (Cote et al., 1998) . In our study of the prognostic value of p27 in human prostate cancer, strong p27 staining was uniformly seen in benign prostatic epithelial components in all tumor sections. p27 staining was variable in prostatic intraepithelial neoplasia and reduced in most prostate cancers. A small subset of tumors, treated with pre-operative androgen ablation therapy prior to radical prostatectomy, tended to show higher expression of p27 protein than that in untreated cases. The few tumors that showed a persistence of low p27 staining (less than 25% of tumor nuclei positive) after androgen ablation therapy had the worst prognosis (Tsihlias et al., 1998) . In their study of p27 expression in prostate cancer, Cordon-Cardo et al. (1998) found low or absent p27 in androgen-independent metastatic prostate cancers. These authors also raised the possibility that mechanisms leading to accelerated p27 degradation may contribute to the development of metastases and/or progression of prostate cancer to the androgen-independent state. Taken together, both studies of p27 in prostate cancer cell lines and in primary tumors raise the hypothesis that changes in pathways that regulate p27 levels may contribute to tumor progression and to growth modulation of human prostate cancer cells in response to various androgenic stimuli.
Materials and methods
Cell culture
The fast growing strain of LNCaP, LNCaP-FGC (Berns et al., 1986) , and cell lines PC-3 and DU145 were purchased from ATCC. Cells were grown in RPMI 1640 culture media plus 5% FBS without phenol red. All experiments were performed using LNCaP passages 25 to 40. Cells were grown to 80% con¯uence in 10 cm tissue culture plates and split 1 : 6. Cell populations growing asynchronously were then treated with variable concentrations (0.1 ± 100 nM) of 5a-dihydrotestosterone (Sigma Laboratories, St. Louis, MO, USA) or ethanol vehicle (0.1% and 1.0%) alone as a control. Cells were treated for up to 96 h, and the media changed every 48 h. As controls, the AR-negative prostate cancer lines PC-3 and DU145 were cultured in DMEM supplemented with 5% FBS without phenol red. Asynchronously growing PC-3 or DU145 cells were treated with 100 nM DHT for 48 h prior to recovery for¯ow cytometry and protein analysis.
Determination of PSA secretion
Cells were cultured on 10 cm plates in 10 ml media. At 30% con¯uence, cells were washed twice with PBS and then cultured with fresh medium with or without addition of 100 nM DHT. Conditioned media were collected at 48 h and PSA concentration determined using the Hybritech assay.
Immunohistochemistry
LNCaP cells were plated on poly-L-lysine coated glass slides and cultured for 24 h. The media was then supplemented with 100 nM DHT and cells cultured for a further 48 h. Cells were then washed in PBS, ®xed in 4% paraformaldehyde containing 0.2% Triton X-100 for 10 min at room temperature. Slides were then blocked with 3% hydrogen peroxide in methanol followed by normal horse serum (10% solution) and then incubated overnight at 48C with anti-p27 monoclonal antibody (Transduction Laboratories, Lexington, p27 in G1 arrest of prostate cancer cells J Tsihlias et al KY, USA) diluted 1 : 1000 (0.25 mg/ml) in PBS. Slides were then reacted with biotin-labeled anti-mouse IgG and incubated with preformed avidin ± biotin ± peroxidase complex (Vector Laboratories, Burlingame, CA, USA). Metalenhanced diaminobenzidine substrate (Pierce, Rockford, IL, USA) was then added in the presence of horseradish peroxidase. Cells were photographed using a Wilovert microscope equipped with a Wild Leitz MPS 52 photocamera (Wild Leitz Ltd., Heerbrugg, Switzerland).
Flow cytometric analysis
Cells were pulse-labeled with 10 mM bromodeoxyuridine (BrdU) for 2 h at intervals after addition of DHT to asynchronously growing cells. Cells were then harvested, ®xed with 70% ethanol, treated with 0.1 N HCl, and heated for 10 min at 958C to expose labeled DNA. Cells were then stained with anti-BrdU-conjugated FITC (Becton Dickinson) and counterstained with propidium iodide. Cell cycle analysis was carried out on a Becton Dickinson FACScan, using Cell Quest software.
Immunoblotting
Cells were lysed in ice cold NP-40 lysis buer (0.1% NP-40, 50 nM Tris pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl¯uoride, and 0.02 mg/ml each of aprotinin, leupepsin, and pepstatin). Lysates were sonicated and clari®ed by centrifugation. Protein was quantitated by Bradford analysis and 20 ± 100 mg protein per lane resolved by SDS ± polyacrylamide gel electrophoresis (SDS ± PAGE). Transfer and blotting was as described (Dulic et al., 1992) . Proteins were detected by electrochemiluminescence (ECL). Densitometry was performed using the Molecular Dynamics Imaging system and ImageQuant software to quantitate the relative amounts of p27 protein detected on Western blots. For detection of cyclin E-associated proteins by immunoprecipitation-Western analysis (IP-Western), cyclin E was immunoprecipitated from 200 mg protein lysate, complexes resolved, blotted and blots reacted with cyclin E, cdk2, p21, and p27 antibodies. For detection of cdk4 complexes, 100 ± 400 mg protein lysate was immunoprecipitated with cdk4 antibody and associated cyclin D1, p15, p16, p21, and p27 proteins detected by immunoblotting. For immunodepletion of p27, p27 was serially immunoprecipitated three times from 200 mg protein lysate and then cyclin E was immunoprecipitated from the p27-depleted lysate. The amounts of immunoprecipitable cyclin E protein, associated cdk2 and p27 proteins, and kinase activities prior to and after p27 immunodepletion were compared using IP-Western blotting and IP-kinase assays.
Oligonucleotide transfections
The sequences of the GS5422 antisense (ASp27) and mismatch p27 GS5585 (MSp27) C-5-propyne modi®ed phosphorothioates used were 5'-TGGCTCTCXTGCGCC-3' and 5'-TGGCTCXCTTGCGCC-3', respectively. X indicates the proprietary`G-clamp' modi®cation of these oligonucleotides, provided by Gilead Sciences. Asynchronously growing cell cultures were transfected with oligonucleotides at a concentration of 50 nM using cytofectin G3815 at 2.5 mg/ml, as described (St.Croix et al., 1996) . After 6 h the transfection cocktail was removed and replaced with complete medium containing 100 nM DHT. Cells were recovered for¯ow cytometric and protein analysis 36 h thereafter. 100 nM DHT-arrested cells were also transfected with ASp27, however, the reduction of p27 was considerably less in these cells than after transfection of ASp27 into asynchronously growing cells. The minor reduction in p27 protein levels in these DHT arrested cells was not sucient to cause release from G0.
Cyclin-dependent kinase assays
Cdk4 kinase assays were performed using the method of Matsushime et al. (1994) , using a truncated recombinant retinoblastoma protein as substrate. Quantitation of radioactivity incorporated in the substrate was performed using a Molecular Dynamics PhosphorImager and ImageQuant software. Cyclin E-associated kinase assays were performed using either a monoclonal anti-cyclin E antibody (mAb E172, from E Harlow, Mass. General, MA, USA) or a polyclonal anticyclin E antibody (from D Agarwaal, Lee Moat Cancer Center, FL, USA). Histone H1 was used as substrate for cyclin E-associated kinase assays. In each case background activity was determined using a non-speci®c antibody as a control. Background activity was subtracted, and kinase activities were graphed as a per cent maximum activity.
Antibodies
The following antibodies were used in the immunoblotting experiments: pRB mouse mAb from Pharmingen; cdk2 rabbit pAb sc-163, cdk4 rabbit pAb sc-260, cdk6 rabbit pAb sc-172, cyclin D1 mouse mAb HD11, cyclin A rabbit pAb sc-596, cyclin B1 mouse mAb sc-245, and p21 rabbit pAb sc-397, all from Santa Cruz Biotechnology, CA, USA; p27 mouse monoclonal antibody from Transduction Laboratories, Lexington, KY, USA. PSA antibody was purchased from DAKO, Denmark. Monoclonal PSTAIRE antibody was a gift from S Reed (The Scripps Research Institute, CA, USA); cyclin D1 mouse mAb DCS-11 and p16 mouse mAb DCS-50, from J Bartek (Danish Cancer Society, Denmark); E12 and E172, mouse monoclonal antibodies to cyclin E from E Harlow (Mass. General, MA, USA); and cdk4 rabbit polyclonal antibody, for use in immunoprecipitation of cdk4, was provided by D Beach (CSH Labs, NY, USA). A monoclonal antibody, JC-6, which recognizes the third ankyrin repeat of human p16 (Enders et al., 1995) and cross reacts with human p15, was used for immunoblotting of p15 in these studies. Results were con®rmed by repeat biologic assays with dierent cell lysates.
